King’s Bigger Bid Still Too Low, Alpharma Board Says

Alpharma urges shareholders to reject King’s $37 per-share bid, as the firm pursues a sale at a higher price.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet